Pure Global
NCT03212937

Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

A Phase I Investigator Sponsored Trial of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export / SINE™ Compound and Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
National Cancer Centre, Singapore·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Selinexor
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Cancer Centre, Singapore
Location
Singapore, Singapore
Timeline & enrollment
Phase
Phase 1
Start date
Jul 01, 2016
End date
Nov 01, 2020
Enrollment
11 participants
Primary outcome

Number of participants with treatment related dose limiting toxicity as assessed by NCI CTCAE v4.0

Summary

This is a single center, open-label, phase I trial with a standard 3+3 dose escalation schema
 to identify the maximum tolerated dose (MTD) of selinexor when combined with ICE. Once MTD is
 determined, there will be an expansion phase and tumor biopsies and peripheral blood will be
 taken pre and post selinexor to examine the study's biologic objectives.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03212937
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03212937 through Pure Global AI's free database. This Phase 1 trial is sponsored by National Cancer Centre, Singapore and is currently Completed. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 11 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.